Preclinical News and Research

RSS

Millennium publishes article on MLN4924 pathway mechanism in lymphoma

Millennium, The Takeda Oncology Company today announced the publication of an article in the journal Blood describing the novel mechanism of action of MLN4924 through targeted pathway modulation in diffuse large B-cell lymphoma (DLBCL).

3 Sep 2010

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.

3 Sep 2010

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Celsion Corporation, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer".

3 Sep 2010

CaPre drug candidate shows promising result on CRP level reduction

Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre on C-reactive protein (CRP) levels, a biomarker of CardioVascular Disease risk (CVD) and associated with diabetes and obesity.

3 Sep 2010

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar (LTX-109) treatment of skin infections caused by Gram positive bacteria.

2 Sep 2010

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).

2 Sep 2010

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Nabi Biopharmaceuticals announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.

2 Sep 2010

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

Martek Biosciences 2010 third quarter revenue increases 51% to $117.2 million

Martek Biosciences Corporation today announced its financial results for the third quarter of fiscal 2010.

2 Sep 2010

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."

31 Aug 2010

NewYork-Presbyterian /Columbia sets up new Myelodysplastic Syndromes Center

NewYork-Presbyterian Hospital/Columbia University Medical Center has established a new center devoted to research and treatment of pre-leukemia blood disorders. Known as the Myelodysplastic Syndromes Center, it is one of the largest programs of its kind in the nation.

31 Aug 2010

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

TPP Global Development Ltd (TPP) announced an agreement with the University of Edinburgh to collaborate on the development of novel pre-clinical intellectual property originated within the University.

31 Aug 2010

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Advanced Life Sciences Holdings, Inc.,a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the publication of a research paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company's core triterpenoid platform technology in the discovery and development of new cancer therapeutic agents.

31 Aug 2010

Amsterdam Molecular first half 2010 net loss in line with last year

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2010.

31 Aug 2010

Cell Therapy Foundation analysis calls for funding in medical research

Some of the most promising medical research conducted to treat diseases of the brain, heart, and circulatory system is moving too slowly to help millions of patients, according to the Cell Therapy Foundation, which advocates the use of adult stem cells to dramatically impact and improve the condition of patients who suffer from a variety of conditions.

31 Aug 2010

HUYA announces strategic partnership with School of Pharmaceutical Sciences at Sun Yat-sen University

HUYA Bioscience International, a company at the forefront of globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the School of Pharmaceutical Sciences at Sun Yat-sen University (SYSU). The collaborative agreement expands HUYA's foothold in Southern China, aiming to accelerate the development of novel drugs arising from the school's research efforts.

30 Aug 2010

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.

30 Aug 2010

Bend Research granted patent for making solid amorphous dispersions of drugs with SDD technology

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announced today that it has received a new U.S. patent covering a process for making spray-dried solid amorphous dispersions of drugs using pressure nozzles.

30 Aug 2010

Ricerca Biosciences completes purification of an API under cGMP controls

Ricerca Biosciences, a uniquely integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the successful completion of the purification of an active pharmaceutical ingredient (API) under current good manufacturing practices (cGMP) controls.

27 Aug 2010

AgeneBio receives grant to develop neural stabilizer therapy for amnestic mild cognitive impairment

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.

27 Aug 2010

Preclinical News and Research

Millennium publishes article on MLN4924 pathway mechanism in lymphoma

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

CaPre drug candidate shows promising result on CRP level reduction

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Martek Biosciences 2010 third quarter revenue increases 51% to $117.2 million

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

NewYork-Presbyterian /Columbia sets up new Myelodysplastic Syndromes Center

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Amsterdam Molecular first half 2010 net loss in line with last year

Cell Therapy Foundation analysis calls for funding in medical research

HUYA announces strategic partnership with School of Pharmaceutical Sciences at Sun Yat-sen University

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Bend Research granted patent for making solid amorphous dispersions of drugs with SDD technology

Ricerca Biosciences completes purification of an API under cGMP controls

AgeneBio receives grant to develop neural stabilizer therapy for amnestic mild cognitive impairment

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News